Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA.

Invest New Drugs. 2018 Aug 7. doi: 10.1007/s10637-018-0630-9. [Epub ahead of print]

PMID:
30083962
2.

Quantitative assessment of gait parameters in people with Parkinson's disease in laboratory and clinical setting: Are the measures interchangeable?

Pau M, Corona F, Pili R, Casula C, Guicciardi M, Cossu G, Murgia M.

Neurol Int. 2018 Jul 4;10(2):7729. doi: 10.4081/ni.2018.7729. eCollection 2018 May 24.

3.

Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma.

Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman EC, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion AR, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst P, Pili R.

Clin Cancer Res. 2018 Jul 30. pii: clincanres.0269.2018. doi: 10.1158/1078-0432.CCR-18-0269. [Epub ahead of print]

PMID:
30061365
4.

The Use of Footstep Sounds as Rhythmic Auditory Stimulation for Gait Rehabilitation in Parkinson's Disease: A Randomized Controlled Trial.

Murgia M, Pili R, Corona F, Sors F, Agostini TA, Bernardis P, Casula C, Cossu G, Guicciardi M, Pau M.

Front Neurol. 2018 May 24;9:348. doi: 10.3389/fneur.2018.00348. eCollection 2018.

5.

Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.

Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, Doñate F, Kollmannsberger CK.

Clin Cancer Res. 2018 May 30. doi: 10.1158/1078-0432.CCR-18-0481. [Epub ahead of print]

PMID:
29848572
6.

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle Ö, Carducci MA, Morris MJ.

JAMA Oncol. 2018 Jul 1;4(7):944-951. doi: 10.1001/jamaoncol.2018.1093.

PMID:
29799999
7.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 May 15. doi: 10.1007/s10456-018-9613-x. [Epub ahead of print] Review.

8.

Low-protein diet in cancer: ready for prime time?

Pili R, Fontana L.

Nat Rev Endocrinol. 2018 May 15. doi: 10.1038/s41574-018-0028-y. [Epub ahead of print] No abstract available.

PMID:
29765134
9.

Electromyographical Gait Characteristics in Parkinson's Disease: Effects of Combined Physical Therapy and Rhythmic Auditory Stimulation.

Bailey CA, Corona F, Murgia M, Pili R, Pau M, Côté JN.

Front Neurol. 2018 Apr 4;9:211. doi: 10.3389/fneur.2018.00211. eCollection 2018.

10.

Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.

Adelaiye-Ogala R, Damayanti NP, Orillion AR, Arisa S, Chintala S, Titus MA, Kao C, Pili R.

Cancer Res. 2018 Jun 1;78(11):2886-2896. doi: 10.1158/0008-5472.CAN-17-3386. Epub 2018 Mar 23.

PMID:
29572225
11.

Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model.

Affronti HC, Long MD, Rosario SR, Gillard BM, Karasik E, Boerlin CS, Pellerite AJ, Foster BA, Attwood K, Pili R, Wilton JH, Campbell MJ, Smiraglia DJ.

Oncotarget. 2017 Oct 20;8(61):103758-103774. doi: 10.18632/oncotarget.21911. eCollection 2017 Nov 28.

12.

Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer.

Ciamporcero E, Daga M, Pizzimenti S, Roetto A, Dianzani C, Compagnone A, Palmieri A, Ullio C, Cangemi L, Pili R, Barrera G.

Free Radic Biol Med. 2018 Feb 1;115:447-457. doi: 10.1016/j.freeradbiomed.2017.12.005. Epub 2017 Dec 14.

PMID:
29248722
13.

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer.

Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, Wang J, Woloszynska-Read A.

Cell Death Dis. 2017 Dec 14;8(12):3217. doi: 10.1038/s41419-017-0024-5.

14.

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.

Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA.

Clin Cancer Res. 2018 Jan 15;24(2):306-315. doi: 10.1158/1078-0432.CCR-17-1100. Epub 2017 Nov 7.

PMID:
29113986
15.

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.

Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R.

Cancer Res. 2017 Dec 1;77(23):6651-6666. doi: 10.1158/0008-5472.CAN-17-0899. Epub 2017 Oct 4.

PMID:
28978636
16.

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).

Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA.

Clin Cancer Res. 2017 Dec 1;23(23):7199-7208. doi: 10.1158/1078-0432.CCR-17-1178. Epub 2017 Sep 22.

PMID:
28939740
17.

Real-Time Multiplex Kinase Phosphorylation Sensors in Living Cells.

Damayanti NP, Buno K, Cui Y, Voytik-Harbin SL, Pili R, Freeman J, Irudayaraj JMK.

ACS Sens. 2017 Aug 25;2(8):1225-1230. doi: 10.1021/acssensors.7b00359. Epub 2017 Jul 13.

PMID:
28838242
18.

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma.

Wentink MQ, Verheul HMW, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Poslinski D, Groman A, Hutson A, Pili R.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30201-X. doi: 10.1016/j.clgc.2017.07.004. [Epub ahead of print]

PMID:
28781191
19.

Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R.

Clin Cancer Res. 2017 Sep 1;23(17):5187-5201. doi: 10.1158/1078-0432.CCR-17-0741. Epub 2017 Jul 11.

PMID:
28698201
20.

Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity.

Sanfrancesco JM, Eble JN, Grignon DJ, Wang M, Zhang S, Sundaram CP, Idrees MT, Pili R, Kouba E, Cheng L.

Mol Carcinog. 2017 Nov;56(11):2527-2537. doi: 10.1002/mc.22699. Epub 2017 Aug 3.

PMID:
28667776
21.

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]).

Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LL, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS.

Clin Genitourin Cancer. 2017 Dec;15(6):642-651.e1. doi: 10.1016/j.clgc.2017.04.023. Epub 2017 Apr 26.

PMID:
28545998
22.

Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.

Mann SA, Lopez-Beltran A, Massari F, Pili R, Fiorentino M, Koch MO, Kaimakliotis HZ, Wang L, Scarpelli M, Ciccarese C, Moch H, Montironi R, Cheng L.

Curr Drug Metab. 2017 Oct 16;18(8):700-711. doi: 10.2174/1389200218666170518162500.

PMID:
28524003
23.

Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.

Marshall JR, Burk RF, Payne Ondracek R, Hill KE, Perloff M, Davis W, Pili R, George S, Bergan R.

Oncotarget. 2017 Apr 18;8(16):26312-26322. doi: 10.18632/oncotarget.15460.

24.

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.

Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA.

Br J Cancer. 2017 Mar 28;116(7):874-883. doi: 10.1038/bjc.2017.33. Epub 2017 Feb 21.

25.

Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab.

Adra N, Cheng L, Pili R.

Clin Genitourin Cancer. 2017 Jun;15(3):e517-e519. doi: 10.1016/j.clgc.2016.12.019. Epub 2016 Dec 29. No abstract available.

26.

Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device.

Huang W, Chang CL, Brault ND, Gur O, Wang Z, Jalal SI, Low PS, Ratliff TL, Pili R, Savran CA.

Lab Chip. 2017 Jan 31;17(3):415-428. doi: 10.1039/c6lc01279e.

PMID:
28054089
27.

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.

Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Gomez EC, Sun Y, Conroy J, Miles KM, Malathi K, Ramaiah S, Anbarasu A, Woloszynska-Read A, Johnson CS, Conroy J, Liu S, Morrison CD, Pili R.

Oncotarget. 2016 Nov 22;7(47):76374-76389. doi: 10.18632/oncotarget.13062.

28.

Genomic profiling of collecting duct renal carcinoma.

Chintala S, Pili R.

Aging (Albany NY). 2016 Oct 26;8(10):2260-2261. doi: 10.18632/aging.101109. No abstract available.

29.

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.

Wentink MQ, Broxterman HJ, Lam SW, Boven E, Walraven M, Griffioen AW, Pili R, van der Vliet HJ, de Gruijl TD, Verheul HM.

Br J Cancer. 2016 Oct 11;115(8):940-948. doi: 10.1038/bjc.2016.275. Epub 2016 Aug 30.

30.

Effects of Physical Rehabilitation Integrated with Rhythmic Auditory Stimulation on Spatio-Temporal and Kinematic Parameters of Gait in Parkinson's Disease.

Pau M, Corona F, Pili R, Casula C, Sors F, Agostini T, Cossu G, Guicciardi M, Murgia M.

Front Neurol. 2016 Aug 11;7:126. doi: 10.3389/fneur.2016.00126. eCollection 2016.

31.

Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.

Deng X, Shao G, Zhang HT, Li C, Zhang D, Cheng L, Elzey BD, Pili R, Ratliff TL, Huang J, Hu CD.

Oncogene. 2017 Mar 2;36(9):1223-1231. doi: 10.1038/onc.2016.287. Epub 2016 Aug 22.

32.

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.

Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, Shen L, Ellis L, Sotomayor P, Swetzig W, Huang R, Conroy D, Orillion A, Das G, Pili R.

BMC Cancer. 2016 Aug 9;16:617. doi: 10.1186/s12885-016-2604-7.

33.

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.

Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP.

Oncotarget. 2016 Aug 30;7(35):56491-56500. doi: 10.18632/oncotarget.10606.

34.

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M.

J Clin Oncol. 2016 Aug 1;34(22):2636-43. doi: 10.1200/JCO.2016.66.9697. Epub 2016 Jun 13.

35.

Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer.

Ellis L, Ku S, Li Q, Azabdaftari G, Seliski J, Olson B, Netherby CS, Tang DG, Abrams SI, Goodrich DW, Pili R.

Prostate. 2016 Sep;76(13):1192-202. doi: 10.1002/pros.23206. Epub 2016 May 26.

PMID:
27225803
36.

[Active ageing and success: A brief history of conceptual models].

Petretto DR, Pili R, Gaviano L, Matos López C, Zuddas C.

Rev Esp Geriatr Gerontol. 2016 Jul-Aug;51(4):229-41. doi: 10.1016/j.regg.2015.10.003. Epub 2016 May 2. Review. Spanish.

PMID:
27156859
37.

Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation.

Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, Miles KM, Conroy JM, Glenn ST, Costantini M, Magi-Galluzzi C, Signoretti S, Choueiri T, Gallucci M, Sentinelli S, Fazio VM, Poeta ML, Liu S, Morrison C, Pili R.

Oncotarget. 2016 May 24;7(21):29901-15. doi: 10.18632/oncotarget.9093.

38.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS.

Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Erratum in: Lancet. 2016 May 14;387(10032):1998.

39.

Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.

Shen L, Orillion A, Pili R.

Epigenomics. 2016 Mar;8(3):415-28. doi: 10.2217/epi.15.118. Epub 2016 Mar 7. Review.

PMID:
26950532
40.

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.

Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME.

Clin Cancer Res. 2016 Mar 15;22(6):1356-63. doi: 10.1158/1078-0432.CCR-15-1432. Epub 2015 Nov 2.

41.

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.

Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, Levine EG, Azabdaftari G, Trump DL, Guru K, George S.

Clin Genitourin Cancer. 2016 Feb;14(1):e59-65. doi: 10.1016/j.clgc.2015.09.013. Epub 2015 Oct 3.

PMID:
26508364
42.

Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model.

Lamming DW, Cummings NE, Rastelli AL, Gao F, Cava E, Bertozzi B, Spelta F, Pili R, Fontana L.

Oncotarget. 2015 Oct 13;6(31):31233-40. doi: 10.18632/oncotarget.5180.

43.

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer.

Kalmuk J, Folaron M, Buchinger J, Pili R, Seshadri M.

Oncotarget. 2015 Sep 15;6(27):24376-92.

44.

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.

Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R.

Oncogene. 2016 Mar 24;35(12):1541-53. doi: 10.1038/onc.2015.219. Epub 2015 Jun 29.

45.

Testicular Cancer, Version 2.2015.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R.

J Natl Compr Canc Netw. 2015 Jun;13(6):772-99.

PMID:
26085393
46.

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga M, Shen L, Schlingemann RO, Pili R, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P.

Angiogenesis. 2015 Jul;18(3):233-44. doi: 10.1007/s10456-015-9462-9. Epub 2015 Apr 1.

47.

Kidney cancer, version 3.2015.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Feb;13(2):151-9.

PMID:
25691606
48.

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature.

Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM.

Oncoscience. 2014 Dec 15;1(12):844-53. eCollection 2014.

49.

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.

Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L.

Oncotarget. 2015 Feb 20;6(5):3136-46.

50.

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R.

Mol Cancer Ther. 2015 Feb;14(2):513-22. doi: 10.1158/1535-7163.MCT-14-0208. Epub 2014 Dec 17.

Supplemental Content

Support Center